Journal article
Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
Bone marrow transplantation (Basingstoke), Vol.43(10), pp.793-800
05/01/2009
DOI: 10.1038/bmt.2008.384
PMID: 19029964
Abstract
The appropriate induction therapy before and the role of maintenance therapy after auto-SCT for patients with multiple myeloma remain areas of active investigation. We conducted a study in 40 patients with bortezomib given sequentially pre-auto-SCT and as maintenance therapy post auto-SCT. Pre-transplant bortezomib was administered for two cycles followed by high-dose melphalan 200 mg/m(2) with auto-SCT of G-CS F-mobilized PBMCs. Post transplant bortezomib was administered weekly for 5 out of 6 weeks for six cycles. No adverse effects were observed on stem cell mobilization or engraftment. An overall response rate of 83% with a CR + very good partial remission (VGPR) of 50% was observed with this approach. Three-year Kaplan-Meier estimates of disease-free survival and overall survival (OS) were 38.2 and 63.1%, respectively. Bortezomib reduced CD8(+) cytotoxic T cell and CD56(+) natural killer cell PBL subsets and was clinically associated with high rates of viral reactivation to varicella zoster. Bone Marrow Transplantation (2009) 43, 793-800; doi:10.1038/bmt.2008.384; published online 24 November 2008
Details
- Title: Subtitle
- Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
- Creators
- G. L. Uy - Washington University in St. LouisS. D. Goyal - Washington University in St. Louis School of MedicineN. M. Fisher - Washington University in St. LouisA. Y. Oza - Washington University in St. LouisM. H. Tomasson - Washington University in St. LouisK. Stockerl-Goldstein - Washington University in St. LouisJ. F. DiPersio - Washington University in St. LouisR. Vij - Washington University in St. Louis
- Resource Type
- Journal article
- Publication Details
- Bone marrow transplantation (Basingstoke), Vol.43(10), pp.793-800
- Publisher
- Springer Nature
- DOI
- 10.1038/bmt.2008.384
- PMID
- 19029964
- ISSN
- 0268-3369
- eISSN
- 1476-5365
- Number of pages
- 8
- Grant note
- Millennium Pharmaceuticals; Takeda Pharmaceutical Company Ltd
- Language
- English
- Date published
- 05/01/2009
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Health and Human Physiology; Internal Medicine
- Record Identifier
- 9984359664902771
Metrics
22 Record Views